Z Gastroenterol 2009; 47(8): 753-757
DOI: 10.1055/s-0028-1109423
Kasuistik

© Georg Thieme Verlag KG Stuttgart · New York

Pregnancy-associated Sweet’s Syndrome in an Acute Episode of Ulcerative Colitis

Sweet-Syndrom in der SchwangerschaftJ. Best1 , A. Dechene1 , S. Esser2 , G. Gerken1 , A. Canbay1
  • 1Department of Gastroenterology and Hepatology, University Hospital Essen
  • 2Department of Dermatology, University Hospital Essen
Further Information

Publication History

manuscript received: 28.9.2008

manuscript accepted: 3.4.2009

Publication Date:
06 August 2009 (online)

Zusammenfassung

Eine im 2. Trimenon schwangere 33-jährige Patientin (15. SSW) mit einer seit Geburt des 1. Kindes bekannten Colitis ulcerosa stellte sich in unserer Klinik aufgrund von neu aufgetretenem, progredientem Gewichtsverlust, Fieber, Leukozytose und blutig/schleimig tingierten Diarrhöen vor. Endoskopisch konnte ein akuter Schub der bekannten Colitis ulcerosa nachgewiesen werden. Wenige Tage später manifestierten sich zusätzlich kutane erythematöse Knötchen und Plaques, anhand von Hautbiopsien wurde die klinische Verdachtsdiagnose einer neutrophilen Dermatitis (Sweet-Syndrom) histologisch gesichert. Eine unverzüglich initiierte, hoch dosierte intravenöse Steroidstoßtherapie erzielte eine unmittelbare Remission, sowohl der kutanen als auch der intestinalen Manifestationen. Beide Krankheitsentitäten weisen eng miteinander assoziierte immunologische Alterationen auf. Pathogenetisch bestehen sowohl bei den Aktivierungsmustern auf Zytokin- und Chemokinebene als auch bei der Aktivierung inflammatorischer Zellreihen signifikante Parallelen. Aktuelle Daten belegen, dass es im Rahmen der Gravidität zu einer Elevation proinflammatorischer Zytokinspiegel kommen kann. Dieses Phänomen spielt möglicherweise eine Schlüsselrolle, sowohl bei der Manifestation intestinaler und extraintestinaler Symptome als auch für den Schweregrad des Krankheitsverlaufs. Im Folgenden werden ein Diagnostikalgorithmus und ein pathogenetischer Erklärungsansatz für das Sweet-Syndrom diskutiert.

Abstract

A 33-year old pregnant patient (pregnancy week 15) with a past medical history of ulcerative colitis with onset of the disease following the birth of her first child was admitted to the hospital with symptoms of weight loss, pyrexia, leukocytosis and bloody and mucous diarrhoea. Total ileocolonoscopy revealed an acute flare of ulcerative colitis. Within a few days, tender erythematous skin lesions occurred and were histologically proven to be neutrophilic dermatosis. Treatment with highly-dosed prednisone led to a complete remission of both cutaneous and intestinal manifestations. Both pathogenic entities are associated with similar immunological alterations, such as comparable cytokine and chemokine release patterns and recruitment of inflammatory cells. Recent data also indicates that proinflammatory cytokine levels are elevated in pregnancy, which might be pivotal in the pathogenesis and the severity of intestinal and extraintestinal symptoms. We present and discuss a diagnostic algorithm and an overall therapeutic rationale for Sweet’s syndrome.

References

  • 1 Cohen P R. Sweet’s syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis.  Orphanet J Rare Dis. 2007;  2 34
  • 2 Canbay A, Runzi M, Gieseler R. et al . Generalized pustulous psoriasis: A novel extraintestinal manifestation of Crohn’s disease?.  Z Gastroenterol. 2001;  39 801-805
  • 3 Yates V M, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn’s disease and ulcerative colitis.  Br J Dermatol. 1982;  106 323-330
  • 4 Cohen P R, Kurzrock R. The pathogenesis of Sweet’s syndrome.  J Am Acad Dermatol. 1991;  25 734
  • 5 Su W P, Liu H N. Diagnostic criteria for Sweet’s syndrome.  Cutis. 1986;  37 167-174
  • 6 Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy.  Rheum Dis Clin North Am. 1997;  23 149-167
  • 7 Langagergaard V, Pedersen L, Gislum M. et al . Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: A Danish nationwide cohort study.  Aliment Pharmacol Ther. 2007;  25 73-81
  • 8 Johnson P J, McFarlane I G, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis.  N Engl J Med. 1995;  333 958-963
  • 9 Vaccaro M, Guarneri F, Guarneri C. et al . Sweet’s syndrome and erythema nodosum after Klebsiella pneumoniae cystitis.  Acta Derm Venereol. 2003;  83 290-291
  • 10 Travis S, Innes N, Davies M G. The South West Gastroenterology Group. . Sweet’s syndrome: an unusual cutaneous feature of Crohn’s disease or ulcerative colitis.  Eur J Gastroenterol Hepatol. 1997;  9 715-720
  • 11 Arai H, Rino Y, Yamanaka S. et al . Lung cancer associated with Sweet’s syndrome: report of a case.  Surg Today. 2008;  38 639-643
  • 12 Cohen P R, Talpaz M, Kurzrock R. Malignancy-associated Sweet’s syndrome: review of the world literature.  J Clin Oncol. 1988;  6 1887-1897
  • 13 Buck T, Gonzalez L M, Lambert W C. et al . Sweet’s syndrome with hematologic disorders: a review and reappraisal.  Int J Dermatol. 2008;  47 775-782
  • 14 Thompson D F, Montarella K E. Drug-induced Sweet’s syndrome.  Ann Pharmacother. 2007;  41 802-811
  • 15 Becuwe C, Delaporte E, Colombel J F. et al . Sweet’s syndrome associated with Crohn’s disease.  Acta Derm Venereol. 1989;  69 444-445
  • 16 Malheiros A P, Teixeira M G, Takahashi M D. et al . Sweet syndrome associated with ulcerative colitis.  Inflamm Bowel Dis. 2007;  13 1583-1584
  • 17 Cohen P R. Pregnancy-associated Sweet’s syndrome: world literature review.  Obstet Gynecol Surv. 1993;  48 584-587
  • 18 Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells.  Nature. 1989;  339 27-30
  • 19 Wegmann T G, Athanassakis I, Guilbert L. et al . The role of M-CSF and GM-CSF in fostering placental growth, fetal growth, and fetal survival.  Transplant Proc. 1989;  21 566-568
  • 20 Paoluzi O A, Crispino P, Amantea A. et al . Diffuse febrile dermatosis in a patient with active ulcerative colitis under treatment with steroids and azathioprine: a case of Sweet’s syndrome. Case report and review of literature.  Dig Liver Dis. 2004;  36 361-366
  • 21 Inglot A D, Gelder F, Georgiades J A. Tumor-associated antigens are cytokine inducers and hyporeactivity factors to the immune system.  Biotherapy. 1998;  11 27-37
  • 22 Filella X, Molina R, Alcover J. et al . Influence of AFP, CEA and PSA on the in vitro production of cytokines.  Tumour Biol. 2001;  22 67-71
  • 23 Weimann E, Reisbach G, Reinsberg J. et al . IL-6 and G-CSF levels in amniotic fluid during the second trimester in normal and abnormal pregnancies.  Arch Gynecol Obstet. 1995;  256 125-130
  • 24 Reinecker H C, Steffen M, Witthoeft T. et al . Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease.  Clin Exp Immunol. 1993;  94 174-181
  • 25 Reuss-Borst M A, Muller C A, Waller H D. The possible role of G-CSF in the pathogenesis of Sweet’s syndrome.  Leuk Lymphoma. 1994;  15 261-264
  • 26 Reuss-Borst M A, Pawelec G, Saal J G. et al . Sweet’s syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease.  Br J Haematol. 1993;  84 356-358
  • 27 Shochat E, Rom-Kedar V, Segel L A. G-CSF control of neutrophils dynamics in the blood.  Bull Math Biol. 2007;  69 2299-2338
  • 28 Le J M, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response.  Lab Invest. 1989;  61 588-602
  • 29 Ohzato H, Yoshizaki K, Nishimoto N. et al . Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery.  Surgery. 1992;  111 201-209
  • 30 Castellheim A, Thorgersen E B, Hellerud B C. et al . New biomarkers in an acute model of live Escherichia coli-induced sepsis in pigs.  Scand J Immunol. 2008;  68 75-84
  • 31 Prat C, Sancho J M, Dominguez J. et al . Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia.  Leuk Lymphoma. 2008;  49 1752-1761
  • 32 Henriksen M, Jahnsen J, Lygren I. et al . C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.  Gut. 2008;  57 1518-1523
  • 33 Kawakami T, Ohashi S, Kawa Y. et al . Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction.  Arch Dermatol. 2004;  140 570-574

PD Dr. Ali Canbay

Gastroenterology and Hepatology, University Hospital Essen

Hufelandstr. 55

45122 Essen

Phone: + + 49/2 01/7 23 36 11

Fax: + + 49/2 01/7 23 59 71

Email: ali.canbay@uni-essen.de

    >